Chris Chapman, M.D.

President, Director and Chief Medical Officer

Chris Chapman, M.D. was appointed as President and Chief Medical Officer of MyMD Pharmaceuticals® effective November 1, 2020. Prior to joining MyMD and since 1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India, and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials, and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible for the supervision of four fellow M.D.s and 10 drug safety specialists. 

Prior to his time at Organon, Dr. Chapman served as Director, Medical Affairs, Drug Safety and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995-2003, where he grew the division from no employees to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff. Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.) from 2007-2016, including as a member of the Audit Committee from 2007-2014, chairperson of the Compensation Committee from 2007-2014, and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects. 

Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria, and tuberculosis, which was organized in 2006. Dr. Chapman is a graduate of the Harvard Kennedy School of Cambridge, Massachusetts for financial management in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown. Prior to his time at Georgetown, Dr. Chapman served in the air force as a B-52 crew chief in the Vietnam era. Dr. Chapman was also the Arthritis Foundations 2021 Medical Honoree.

  • Professional Activities
  • Research and Publications
  • Harvard Kennedy School December 2020 Financial Management
  • As a graduate of the Harvard Kennedy School of Cambridge, Massachusetts, I have a working knowledge of crafting a logic model narrative that presents inputs, resources, outputs, and expectations for individual programs. I am familiar with the unique aspects of the financial statements for a nonprofit organization as well as creating forecasting and budget models.
  • Georgetown University School of Medicine 1987 Medical Doctor, M.D. 
  • Georgetown University School of Medicine 1988 Internal Medicine Internship 
  • Georgetown University School of Medicine 1989 Anesthesiology Residency 
  • Georgetown University School of Medicine 1991 Obstetric, Pediatric Anesthesiology Fellowship 

The following three publications for MyMD Pharmaceuticals, Inc. were published/accepted in Q3 or 2022 (1&2) and Q1 of 2023 (3).

  1. Journal of Drug Research
    A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose of MYMD1™ Capsules in Healthy Male and Female Adult Subjects

    Citation: Brager J, Chapman C, Dunn L, Kaplin A. A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects. Drug Res (Stuttg). 2022 Nov 11. doi: 10.1055/a-1962-6834. Epub ahead of print. PMID: 36368677.

  2. British Society of Immunology, Liverpool, UK December 5-8, 2022
    Pharmacology and clinical profile of MYMD-1® (isomyosamine), an oral, selective, next-generation, TNF-alpha inhibitor that crosses the blood brain barrier
    Jenna Brager, Ronald Christopher, Adam Kaplin, Chris Chapman
  3. 62nd Annual Meeting and ToxExpo, Society of Toxicology March 19-23, 2023 in Nashville, TN
    A Naturally Occurring Novel Therapeutic and Oral Selective Inhibitor of TNFa, MYMD-1 (Isomyosamine), Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody-Induced Arthritis
    Chris Chapman, and Sonia Edaye
  • This field is for validation purposes and should be left unchanged.